Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House

Executive Summary

The 2017 user fee reauthorization bill contains provisions that should be significantly easier for the agency to implement compared with the 2012 measure. Senate clears clean bill for president's review.

Advertisement

Related Content

OTC Monograph User Fees Still On The Table, But Not In Legislation
FDA Planning For Possible Doubling Of HQ-Based Staff In 15 Years
US FDA Planning For Possible Doubling Of HQ-Based Staff In 15 Years
FDA Planning For Possible Doubling Of HQ-Based Staff In 15 Years
Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
FDA Gives Congress Reprieve On Deadline For Passing User Fee Bill
FDA Exploring Whether Public Shaming Can Stop REMS Abuses
White House Slams Generic Exclusivity Provisions In User Fee Bill
User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases
Janet Woodcock: FDASIA was landmark legislation in US drug regulation but sequester threatens success

Topics

Advertisement
UsernamePublicRestriction

Register

PS121258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel